Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making.
Oberije C, Nalbantov G, Dekker A, Boersma L, Borger J, Reymen B, van Baardwijk A, Wanders R, De Ruysscher D, Steyerberg E, Dingemans AM, Lambin P. Oberije C, et al. Among authors: dingemans am. Radiother Oncol. 2014 Jul;112(1):37-43. doi: 10.1016/j.radonc.2014.04.012. Epub 2014 May 17. Radiother Oncol. 2014. PMID: 24846083 Free PMC article.
18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study.
van Loon J, Offermann C, Bosmans G, Wanders R, Dekker A, Borger J, Oellers M, Dingemans AM, van Baardwijk A, Teule J, Snoep G, Hochstenbag M, Houben R, Lambin P, De Ruysscher D. van Loon J, et al. Among authors: dingemans am. Radiother Oncol. 2008 Apr;87(1):49-54. doi: 10.1016/j.radonc.2008.02.019. Epub 2008 Mar 14. Radiother Oncol. 2008. PMID: 18342967
Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Fatah SA, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D. van Loon J, et al. Among authors: dingemans am. Eur J Cancer. 2009 Mar;45(4):588-95. doi: 10.1016/j.ejca.2008.10.017. Epub 2008 Dec 4. Eur J Cancer. 2009. PMID: 19046631
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients.
Nalbantov G, Kietselaer B, Vandecasteele K, Oberije C, Berbee M, Troost E, Dingemans AM, van Baardwijk A, Smits K, Dekker A, Bussink J, De Ruysscher D, Lievens Y, Lambin P. Nalbantov G, et al. Among authors: dingemans am. Radiother Oncol. 2013 Oct;109(1):100-6. doi: 10.1016/j.radonc.2013.08.035. Epub 2013 Sep 14. Radiother Oncol. 2013. PMID: 24044794 Free article.
PD-(L)1 Inhibition and Cardiac Damage: A Relevant Toxicity?
De Ruysscher D, Dingemans AM, Vooijs M, Heymans S. De Ruysscher D, et al. Among authors: dingemans am. J Thorac Oncol. 2018 Apr;13(4):478-479. doi: 10.1016/j.jtho.2018.02.008. J Thorac Oncol. 2018. PMID: 29576288 Free article. No abstract available.
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B. Hendriks LEL, et al. Among authors: dingemans am. J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16. J Thorac Oncol. 2019. PMID: 30780002 Free article.
358 results